Beta-Blocker Treatment for Pediatric Congenital Heart Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for congenital heart defects (CHD) associated with low cardiomyocyte endowment, such as Tetralogy of Fallot, are inadequate in preventing heart failure and arrhythmias, and there is a lack of effective treatments to address the increased risk of heart failure and arrhythmias in patients post-surgery.
Innovation Solution
Administering a nonspecific beta-blocker, β1-beta blocker, or β2-beta blocker to patients with CHD to induce cardiomyocyte cytokinesis and expand cardiomyocyte endowment, thereby reducing binucleated cells and improving heart function and resilience to injuries like myocardial infarction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If surgery is performed to decrease hemodynamic load in CHD patients, then immediate hemodynamic improvement is achieved, but lifetime risk of heart failure and arrhythmia remains significantly increased
Solution Approach 1:
The patent applies preliminary action by administering beta-blockers to pediatric patients before the heart completes its natural growth and cardiomyocyte proliferation period (before 6 months past term). This timing allows the medication to influence cardiomyocyte cytokinesis during the critical window when the heart is still developing, potentially preventing long-term heart failure and arrhythmia risks before they manifest
Solution Approach 2:
The patent changes the pharmacological parameter by using beta-blockers at specific dosages and durations tailored to pediatric patients with CHD. This involves adjusting the concentration and exposure time of the beta-blocker to achieve therapeutic effects on cardiomyocyte cytokinesis while minimizing side effects, thereby addressing the long-term reliability issue
2Quantity of substance
If beta-blockers are administered to induce cardiomyocyte cytokinesis, then cardiomyocyte endowment increases by at least 5%, but the mechanism of action is not fully understood in pediatric CHD patients
Solution Approach 1:
The patent employs feedback by monitoring clinical outcomes and cardiomyocyte responses in pediatric patients receiving beta-blocker treatment. Through observational studies and clinical data collection, the research seeks to understand the relationship between beta-blocker administration and cardiomyocyte cytokinesis, gradually building knowledge about the mechanism while treating patients
Solution Approach 2:
The patent applies self-service by utilizing the natural physiological processes of cardiomyocyte cytokinesis and heart development in pediatric patients. The beta-blockers work by modulating endogenous signaling pathways that already exist in developing hearts, allowing the body's own mechanisms to produce the therapeutic effect of increased cardiomyocyte endowment
3Reliability
If current therapies are used for CHD patients, then survival rates have increased enabling one million patients to live with CHD, but effective treatments to prevent heart failure and arrhythmia are still lacking
Solution Approach 1:
The patent applies universality by proposing a beta-blocker treatment regimen that could potentially benefit multiple types of CHD patients with low cardiomyocyte endowment. The approach uses a commonly available class of medications (beta-blockers) already used in cardiology, making the treatment broadly applicable across different CHD conditions rather than requiring specialized or rare therapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method increases cardiomyocyte endowment by at least 5% and improves heart function, reducing the risk of complications associated with heart failure and arrhythmias, thereby enhancing the long-term survival and quality of life for patients with CHD.
Implementation Method 1
Beta-blockers function by blocking the binding of epinephrine and norepinephrine to beta-adrenergic receptors, thereby preventing the downstream signaling that leads to cardiomyocyte binucleation and cytokinesis failure
Implementation Method 2
Beta-blockers promote successful cardiomyocyte cytokinesis, the process by which a single cell divides into two daughter cells, thereby increasing the number of functional cardiomyocytes and expanding cardiomyocyte endowment in patients with congenital heart defects
Data Source
AI summary
Provided herein are methods of treating congenital heart disease in a patient, such as tetralogy of Fallot, with beta blockers to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient. Also provided herein are uses for beta blockers for treating congenital heart disease, such as tetralogy of Fallot, in a patient to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient.